Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 1121-1126

  Baumann, Marcus ^a   Sollinger, Daniel ^a   Roos, Marcel ^a   Lutz, Jens ^a   Heemann, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEART; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; TELEMETRY;

AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BENZIMIDAZOLES; BLOOD PRESSURE; CARDIOMEGALY; CORONARY VESSELS; HYPERTENSION; MALE; MYOCARDIUM; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; TIME FACTORS; TUNICA MEDIA;

EID: 77249084312     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161075     Document Type: Article

References (26)

1. Baumann M, Hermans JJ, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, Smits JF, and Boudier HA (2007a) Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens 25:2504-2511.
2. Baumann M, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, Smits JF, and Struijker Boudier HA (2007b) Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25:207-215.
3. Baumann M, Janssen BJ, Rob Hermans JJ, Bartholome R, Smits JF, and Struijkerboudier HA (2009) Renal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive rats. Acta Physiol (Oxf) 196:231-237.
4. Baumann M and van den Born BJ (2006) Treating prehypertension. N Engl J Med 355:416-418.
5. Berecek KH, Nagahama S, and Oparil S (1984) Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat. J Hypertens Suppl 2:S63-S66.
6. Bergman MR, Kao RH, McCune SA, and Holycross BJ (1999) Myocardial tumor necrosis factor-α secretion in hypertensive and heart failure-prone rats. Am J Physiol 277:H543-H550.
7. Bergström G, Johansson I, Wickman A, Gan L, and Thorup C (2002) Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure. J Hypertens 20:1413-1421.
8. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, and Roccella EJ (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 52:818-827.
9. Grassi DG (2006) Treating prehypertension. N Engl J Med 355:416-418.
10. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG, and Rudolph AE (2002) Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 283:H1775-H1784.
11. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685-1697.
12. Kacimi R and Gerdes AM (2003) Alterations in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension 41:968-977.
13. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, and He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217-223.
14. Liang Q, Elson AC, and Gerdes AM (2006) p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail 12:479-486.
15. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, et al. (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487-1496.
16. Lutz J, Luong le A, Strobl M, Deng M, Huang H, Anton M, Zakkar M, Enesa K, Chaudhury H, Haskard DO, et al. (2008) The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med 86:1329-1339.
17. Meltzer JI (2006) A specialist in clinical hypertension critiques the TROPHY trial. Am J Hypertens 19:1098-1100.
18. Nesbitt SD (2007) Treatment options for prehypertension. Curr Opin Nephrol Hypertens 16:250-255.
19. Persell SD and Baker DW (2006) Studying interventions to prevent the progression from prehypertension to hypertension: does TROPHY win the prize? Am J Hypertens 19:1095-1097.
20. Rakusan K, Cicutti N, Kazda S, and Turek Z (1994) Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats. Hypertension 24:205-211.
21. cp-rats) in comparison with Wistar rats during aging. Basic Res Cardiol 98:275-284.
22. Shigenaga A, Tamura K, Wakui H, Masuda S, Azuma K, Tsurumi-Ikeya Y, Ozawa M, Mogi M, Matsuda M, Uchino K, et al. (2008) Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule. Hypertension 52:672-678.
23. Slama M, Ahn J, Varagic J, Susic D, and Frohlich ED (2004) Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: effects of hypertension and age. Am J Physiol Heart Circ Physiol 286:H181-H185.
24. Tanaka Y, Tamura K, Koide Y, Sakai M, Tsurumi Y, Noda Y, Umemura M, Ishigami T, Uchino K, Kimura K, et al. (2005) The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Lett 579:1579-1586.
25. Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, and Julius S (2008) An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY). J Clin Hypertens (Greenwich) 10:436-442.
26. Wu JN, Edwards D, and Berecek KH (1994) Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension 23:819-822.